Advanced Skin Cancer Diagnostic Tests Overlay Biology on Top of Pathology to Determine...

Advanced Skin Cancer Diagnostic Tests Overlay Biology on Top of Pathology to Determine Appropriate Treatment


An Empowered Patient Podcast hosted by Karen Jagoda


Derek Maetzold, President and CEO of Castle Biosciences is harnessing the power of genomics to understand the biology of skin cancer.


Castle has developed genomic tests to determine how aggressive melanoma and squamous cell carcinoma are in order to better inform dermatologist and patients about intervention decisions. With both diagnostic and prognostic tests and assist from artificial intelligence machine learning-based algorithms, calculations are made for assessing the risk of developing metastatic disease for each individual patient.

Listen to Podcast: https://empoweredpatientradio.com/advanced-skin-cancer-diagnostic-tests-overlay-biology-on-top-of-pathology-to-determine-appropriate-treatment


Transcript of Podcast: https://empoweredpatientradio.com/advanced-skin-cancer-diagnostic-tests-overlay-biology-on-top-of-pathology-to-determine-appropriate-treatment-transcript

Castle Biosciences website: https://www.castlebiosciences.com




  • LinkedIn Basic Black
  • Twitter Basic Black

FC Global Strategies LLC

Tel. +1 646 450 8909

Email info@fcglobalstrategies.com

Website www.fcglobalstrategies.com

389 Corona Street, Suite 589

Denver CO 80218 USA

 

© 2021 FC Global Strategies LLC